Monotherapy in Patients with Type 2 Diabetes Mellitus
Authors:
- Sang Youl RheeSRSang Youl Rhee
- Hyun Jin KimHKHyun Jin Kim
- Seung-Hyun KoSKSeung-Hyun Ko
- Byung-Wan LeeBLByung-Wan Lee
- Kyung Mook ChoiKCKyung Mook Choi
- Committee of Clinical Practice Guideline of Korean Diabetes AssociationCACommittee of Clinical Practice Guideline of Korean Diabetes Association
Open Access
- 1 January 2017
- journal article
- review article
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 41 (5) , 349-356
Abstract
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly.Keywords
Funding Information
- Korean Diabetes Association
This publication has 64 references indexed in Scilit:
- Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy StudyDiabetes & Metabolism Journal, 2011
- The Effect of Oral Antidiabetic Agents on A1C LevelsDiabetes Care, 2010
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Efficacy and Safety of Mitiglinide in Korean Type 2 Diabetic Patients: Prospective Randomised Multicenter Comparative Phase III StudyThe Journal of Korean Diabetes Association, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998